Tenecteplase Improves Door-to-Needle Time in Real-World Acute Stroke Treatment.

ABSTRACT:

Background

We report the interim results of a process improvement initiative at a comprehensive stroke center in which all tPA (tissue-type plasminogen activator)-eligible patients were given tenecteplase for acute ischemic stroke.

Methods

We retrospectively analyzed a prospectively maintained single-center registry of consecutive patients with acute ischemic stroke treated at our comprehensive stroke center emergency department or transferred for further care. Patients treated with alteplase (tPA) before the process improvement initiative (October 2019-April 2020) were compared with those treated with tenecteplase (May 2020-July 2021). The primary efficacy outcome was the Target: Stroke Phase II recommendation of door-to-needle (DTN) time ≤45 minutes. Backward stepwise logi

SUBMITTER: Hall J 

PROVIDER: S-EPMC12512332 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature